IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer

Lisanne Heim,Zuqin Yang,Patrick Tausche,Katja Hohenberger,Mircea T. Chiriac,Julia Koelle,Carol-Immanuel Geppert,Katerina Kachler,Sarah Miksch,Anna Graser,Juliane Friedrich,Rakshin Kharwadkar,Ralf J. Rieker,Denis I. Trufa,Horia Sirbu,Markus F. Neurath,Mark H. Kaplan,Susetta Finotto
DOI: https://doi.org/10.3389/fimmu.2022.859738
IF: 7.3
2022-04-20
Frontiers in Immunology
Abstract:Although lung cancer is the leading cause of cancer deaths worldwide, the mechanisms how lung cancer cells evade the immune system remain incompletely understood. Here, we discovered IL-9-dependent signaling mechanisms that drive immune evasion in non-small cell lung cancer (NSCLC). We found increased IL-9 and IL-21 production by T cells in the tumoral region of the lung of patients with NSCLC, suggesting the presence of Th9 cells in the lung tumor microenvironment. Moreover, we noted IL-9 producing Tregs in NSCLC. IL-9 target cells in NSCLC consisted of IL-9R+ tumor cells and tumor-infiltrating lymphocytes. In two murine experimental models of NSCLC, and in vitro , IL-9 prevented cell death and controlled growth of lung adenocarcinoma cells. Targeted deletion of IL-9 resulted in successful lung tumor rejection in vivo associated with an induction of IL-21 and reduction of Treg cells. Finally, anti-IL-9 antibody immunotherapy resulted in suppression of tumor development even in established experimental NSCLC and was associated with reduced IL-10 production in the lung. In conclusion, our findings indicate that IL-9 drives immune escape of lung tumor cells via effects on tumor cell survival and tumor infiltrating T cells. Thus, strategies blocking IL-9 emerge as a new approach for clinical therapy of lung cancer.
immunology
What problem does this paper attempt to address?